Medpace Holdings Inc. (MEDP) reported better-than-expected Q2 2026 financial results, surpassing analyst consensus for both earnings and revenue. The company also significantly raised its fiscal year 2026 guidance, driven by a growing project backlog and strong net new business awards, leading to a substantial increase in its stock price.
Medpace Holdings Inc. (MEDP) delivered a strong Q2 2026 performance, exceeding analyst expectations for both earnings per share and revenue. This positive surprise, coupled with a healthy 4.9% year-over-year growth in its project backlog to over $3.01 billion and a robust net book-to-bill ratio of 1.13x, indicates strong operational momentum. The company's decision to raise its fiscal 2026 earnings and revenue guidance significantly signals management's confidence in continued growth. This news is a major positive catalyst for MEDP, suggesting sustained demand for its clinical contract research services and a favorable outlook for investors in the short to medium term.